It's a Big Day for Seniors Who Want GLP-1s

Medicare just opened a big door for older Americans chasing the new class of weight-loss drugs. A federal pilot "bridge" program that launched Wednesday will let certain Medicare beneficiaries get GLP-1 medications for obesity for a flat $50 monthly copay—even if they don't have another qualifying condition like diabetes—through the end of 2027.

The impact estimates vary: ABC News cites a new KFF analysis based on 2023 data that estimates 3.8 million people could qualify; the Wall Street Journal reports a far higher 12.5 million to 20 million could be eligible. But the path isn't without its obstacles: those with a BMI under 35 will need to have other specified health issues to qualify, and prior authorization is required, meaning Medicare will have to OK a prescriber's request before the prescription can be filled. The program covers pills and multi-dose injection pens of drugs including Wegovy, Zepbound, and Foundayo, but not single-dose Zepbound pens or vials.